Efficacy and Safety of Benmelstobart Plus Anlotinib in Advanced Endometrial Cancer: Results of a Multi-Cohort, Phase II Study (ETER200).

Liang S, Chen X, Wang K, Wang D, An R, Hou J, Yang Y, Wang D, Qu P, Zhang B, Duan W, Li X, Zang A, Yu G, Lou H, Yao D, Wang S, Yan D, Li L, Liu X, Zhao W, Chen Z, Fei J, Li J, Wang J, Wang Z, Yao S, Ning F, Zhou H, Sun L, Pan L, Liu Q, Yang H, Wang L, Zhang M, Chen X, Yuan J, Zhang X, Zhang Y, Liao Q, Wu X

Open source

DOI: 10.1002/mco2.71081
Published: 2026 Nov
Container: MedComm
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/mco2.71081,
  title = {Efficacy and Safety of Benmelstobart Plus Anlotinib in Advanced Endometrial Cancer: Results of a Multi-Cohort, Phase II Study (ETER200).},
  author = {Liang S and Chen X and Wang K and Wang D and An R and Hou J and Yang Y and Wang D and Qu P and Zhang B and Duan W and Li X and Zang A and Yu G and Lou H and Yao D and Wang S and Yan D and Li L and Liu X and Zhao W and Chen Z and Fei J and Li J and Wang J and Wang Z and Yao S and Ning F and Zhou H and Sun L and Pan L and Liu Q and Yang H and Wang L and Zhang M and Chen X and Yuan J and Zhang X and Zhang Y and Liao Q and Wu X},
  year = {2026},
  journal = {MedComm},
  doi = {10.1002/mco2.71081},
  url = {https://doi.org/10.1002/mco2.71081}
}

RIS

TY  - JOUR
TI  - Efficacy and Safety of Benmelstobart Plus Anlotinib in Advanced Endometrial Cancer: Results of a Multi-Cohort, Phase II Study (ETER200).
AU  - Liang S
AU  - Chen X
AU  - Wang K
AU  - Wang D
AU  - An R
AU  - Hou J
AU  - Yang Y
AU  - Wang D
AU  - Qu P
AU  - Zhang B
AU  - Duan W
AU  - Li X
AU  - Zang A
AU  - Yu G
AU  - Lou H
AU  - Yao D
AU  - Wang S
AU  - Yan D
AU  - Li L
AU  - Liu X
AU  - Zhao W
AU  - Chen Z
AU  - Fei J
AU  - Li J
AU  - Wang J
AU  - Wang Z
AU  - Yao S
AU  - Ning F
AU  - Zhou H
AU  - Sun L
AU  - Pan L
AU  - Liu Q
AU  - Yang H
AU  - Wang L
AU  - Zhang M
AU  - Chen X
AU  - Yuan J
AU  - Zhang X
AU  - Zhang Y
AU  - Liao Q
AU  - Wu X
PY  - 2026
JO  - MedComm
DO  - 10.1002/mco2.71081
UR  - https://doi.org/10.1002/mco2.71081
ER  -

APA

S, L., X, C., K, W., D, W., R, A., J, H., Y, Y., D, W., P, Q., B, Z., W, D., X, L., A, Z., G, Y., H, L., D, Y., S, W., D, Y., L, L., X, L., W, Z., Z, C., J, F., J, L., J, W., Z, W., S, Y., F, N., H, Z., L, S., L, P., Q, L., H, Y., L, W., M, Z., X, C., J, Y., X, Z., Y, Z., Q, L., & X, W. (2026). Efficacy and Safety of Benmelstobart Plus Anlotinib in Advanced Endometrial Cancer: Results of a Multi-Cohort, Phase II Study (ETER200).. MedComm. https://doi.org/10.1002/mco2.71081

Source records

pubmed · retrieved 2026-11-10T08:38:16.705Z